Anteris Technologies

Happy Holidays from the Anteris team! 🎄🎊🕎⛄ We dialed up the creative energy with a spirit week, including ugly holiday sweaters and decades day! We wish everyone a joyous holiday season and look forward to more excitement in 2025! #ProudtobeAnteris

On December 13, Anteris Technologies Global Corp. commenced trading on the NASDAQ stock exchange, raising $88 million. This funding will enable us to advance along our path to commercializing the novel biomimetic DurAVR® Transcatheter Heart Valve. Thank you to our investors – we look forward to shaping the future of cardiac care together! Learn more: https://lnkd.in/gCrayzkM #NASDAQ #MedTech #ProudtobeAnteris #DareToDoMore This does not constitute an offer to sell or the solicitation of an offer to buy any securities of Anteris Technologies Global Corp. DurAVR® INVESTIGATIONAL USE ONLY. NOT AVAILABLE FOR COMMERCIAL SALE. EU: Exclusively for clinical investigations. US: CAUTION – Investigational Device. Limited by Federal (or United States) law to investigational use.

We are listed! ✔️ We are thrilled to announce that Anteris Technologies has officially listed on the Nasdaq stock exchange under the ticker symbol "AVR." This milestone marks a significant step forward in our mission to discovering, developing and commercializing innovative medical devices designed to improve the quality of life for patients with aortic stenosis. This is a momentous occasion for our company, a testament to the tireless efforts and unwavering tenacity of our employees and physician partners. We look forward to continuing to move the conversation forward in TAVR! Learn more: https://lnkd.in/gCrayzkM This does not constitute an offer to sell or the solicitation of an offer to buy any securities of Anteris Technologies Global Corp. #NASDAQ #MedTech #ProudtobeAnteris #DareToDoMore

Healthy native flow patterns may not have been the design target for commercially available TAVR valves—but the impact of restoring laminar flow could demonstrate incredible upstream and downstream benefits.* In this video, Dr. João Cavalcante discusses what laminar flow is and why it’s important.   #LaminarFlow #TAVR #TAVI #interventionalcardiology #MovingtheConversationForward    *Sources:  Garg P, Markl M, Sathananthan J, Sellers SL, Meduri C, Cavalcante J. Restoration of flow in the aorta: a novel therapeutic target in aortic valve intervention. Nat Rev Cardiol. 2024;21(4):264-273 .  Chirinos JA, Akers SR, Schelbert E, et al. Arterial Properties as Determinants of Left Ventricular Mass and Fibrosis in Severe Aortic Stenosis: Findings From ACRIN PA 4008. J Am Heart Assoc. 2019;8(1):e010271.     DurAVR® INVESTIGATIONAL USE ONLY. NOT AVAILABLE FOR COMMERCIAL SALE. EU: Exclusively for clinical investigations. US: CAUTION – Investigational Device. Limited by Federal (or United States) law to investigational use.

Anteris, in partnership with leading imaging expert Dr. Pankaj Garg, is pioneering the growing evidence of the importance of healthy, laminar flow in TAVR. Yesterday at London Valves Dr. Garg presented cutting-edge cardiac MRI analyses, which compared flow dynamics and LV function between DurAVR® THV recipients and a healthy control group. These promising data highlight the potential of DurAVR® THV to mimic the performance of a healthy aortic valve as a result of the valve's biomimetic design. We are excited to continue partnering with experts like Dr. Garg to move the conversation forward in aortic stenosis and advance the definition of success in TAVR.     Here were some of the key takeaways:  ➡ DurAVR® THV’s biomimetic design provides healthy flow patterns, as measured by flow displacement (FD) and flow reversal ratios (FRR).  ➡ Aortic function with DurAVR® THV was similar to healthy controls, measured by left ventricle (LV) end-diastolic volume, LV end-systolic volume, and LV mass.  ➡ LV mass decreased in patients treated with DurAVR® THV compared to baseline, suggesting an improvement in LV unloading.  ➡ In paired analysis, DurAVR® THV restored LV mass to similar to a healthy control.     Sign up here to receive future data updates: https://lnkd.in/gjNt679x    #TAVI #TAVR #aorticstenosis #laminarflow #PCRLV #MovingtheConversationForward DurAVR® INVESTIGATIONAL USE ONLY. NOT AVAILABLE FOR COMMERCIAL SALE.  EU: Exclusively for clinical investigations. US: CAUTION – Investigational Device. Limited by Federal (or United States) law to investigational use. 

Tune in tomorrow for these DurAVR® THV presentations at London Valves! Dr. Magnus Settergren will share his experience in a rare TAV-in-TAV-in-SAV case, and Dr. Pankaj Garg will present his MRI research with DurAVR® THV, including flow dynamics and LV mass data. #PCRLV #TAVI #TAVR #laminarflow #aorticstenosis DurAVR® INVESTIGATIONAL USE ONLY. NOT AVAILABLE FOR COMMERCIAL SALE.  EU: Exclusively for clinical investigations. US: CAUTION – Investigational Device. Limited by Federal (or United States) law to investigational use. 

Just released! In this panel discussion from TCT, hear from Drs. Amar Krishnaswamy, Nicolas Van Mieghem, and Bernard Prendergast as they review the latest DurAVR® THV MRI flow and LV mass data compared to a healthy matched control group.* Learn about the impact of valve design on restoration of laminar flow and the potential impact of valve flow dynamics on disease regression and long-term patient outcomes after TAVR.   Watch full video ➡ https://lnkd.in/gKXDfvEb #TCT2024 #laminarflow #TAVR #TAVI #aorticstenosis #MovingtheConversationForward   *Source: Krishnaswamy A. DurAVR® THV: Regression of LV Mass After TAVR Using a Novel Biomimetic Valve Design. Oral presentation at: TCT Conference; October 2024; Washington, D.C.   DurAVR® INVESTIGATIONAL USE ONLY. NOT AVAILABLE FOR COMMERCIAL SALE. EU: Exclusively for clinical investigations. US: CAUTION – Investigational Device. Limited by Federal (or United States) law to investigational use.

Attending PCR London Valves? Don’t miss Dr. Pankaj Garg’s presentation on laminar flow and LV mass regression, featuring data from DurAVR® THV cases! In this presentation, learn about flow dynamics and the potential impact on disease regression and patient outcomes after TAVI.    #LaminarFlow #TAVI #TAVR #MovingtheConversationForward #PCRLV    DurAVR® INVESTIGATIONAL USE ONLY. NOT AVAILABLE FOR COMMERCIAL SALE.  EU: Exclusively for clinical investigations. US: CAUTION – Investigational Device. Limited by Federal (or United States) law to investigational use.

At PCR London Valves, Dr. Andreas Rück will present about his experience with DurAVR® THV in a rare TAV-in-TAV-in-SAV case from earlier this year. The DurAVR® valve was implanted via compassionate use approval in Sweden. Dr. Rück will present case footage and firsthand insights. “DurAVR® allowed us to treat a patient who was deemed unsuitable for surgical intervention or in fact other TAVRs. The device was easy to use and allowed us to implant the valve in a predictable way. Further, it has provided the patient with the best functioning valve since before his first valve replacement, this despite it being placed inside two other valves.” - Dr Andreas Rück #ViV #valveinvalve #TAVI #TAVR #aorticstenosis #PCRLV DurAVR® INVESTIGATIONAL USE ONLY. NOT AVAILABLE FOR COMMERCIAL SALE.   EU: Exclusively for clinical investigations. US: CAUTION – Investigational Device. Limited by Federal (or United States) law to investigational use. 

Aortic stenosis impacts not only the valve but also the left ventricle (LV). In this video, Drs. João Cavalcante and Christopher Meduri discuss why LV mass is important to monitor in aortic stenosis patients. #aorticstenosis #TAVR #TAVI #cardiachypertrophy #MovingtheConversationForward DurAVR® INVESTIGATIONAL USE ONLY. NOT AVAILABLE FOR COMMERCIAL SALE.  EU: Exclusively for clinical investigations. US: CAUTION – Investigational Device. Limited by Federal (or United States) law to investigational use.